c-Src and EGFR Inhibition in Molecular Cancer Therapy: What Else Can We Improve?

Volume: 12, Issue: 6, Pages: 1489 - 1489
Published: Jun 7, 2020
Abstract
The proto-oncogene c-Src is a non-receptor tyrosine kinase playing a key role in many cellular pathways, including cell survival, migration and proliferation. c-Src de-regulation has been observed in several cancer types, making it an appealing target for drug discovery efforts. Recent evidence emphasizes its crucial role not only in promoting oncogenic traits, but also in the acquisition and maintenance of cancer resistance to various...
Paper Details
Title
c-Src and EGFR Inhibition in Molecular Cancer Therapy: What Else Can We Improve?
Published Date
Jun 7, 2020
Journal
Volume
12
Issue
6
Pages
1489 - 1489
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.